InfaCare Pharmaceuticals
About InfaCare Pharmaceuticals
InfaCare Pharmaceuticals is a Healthcare company based in Feasterville Trevose (United States) founded in 2001, and was acquired by Mallinckrodt Pharmaceuticals in September 2017. Products for the neonatal and pediatric patient population. InfaCare Pharmaceuticals has raised $78.15 million across 14 funding rounds from investors including Mallinckrodt Pharmaceuticals, FirstMark and Atlas Venture. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune; 3 of its 3 listed competitors have raised funding.
Company details
InfaCare Pharmaceuticals was founded in 2001 and is based in Feasterville Trevose, United States. Operations focus on the specialty pharmaceutical sector, where treatments for neonatal and pediatric conditions are developed and brought to market. The lead product, Stanatea decyclizing heme oxygenase inhibitoris being advanced for hyperbilirubinemia in infants. Completion of the phase IIB Jasmine trial for stannsoporfin in neonates has been achieved.
- Headquarters Feasterville Trevose, United States
- Stage Acquired
- SectorsHealthcare
- Website infacare.com
- Social LinkedIn
- Acquired by Mallinckrodt Pharmaceuticals (Sep 2017)
- Total Equity Funding$78.15M (USD)
in 14 rounds
- Latest Funding Round$3.5M (USD), Series C
Jun 2017
- InvestorsMallinckrodt Pharmaceuticals
& 5 more
- Acquired byMallinckrodt Pharmaceuticals
(Sep 2017)
Funding Insights of InfaCare Pharmaceuticals
InfaCare Pharmaceuticals has successfully raised a total of $78.15M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $3.5 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78.15M
- Total Rounds 14
- Last Round Series C — $3.5M
- First Round $75,000
(May 2002)
- Investors Count 5
Latest 10 of 14 funding rounds of InfaCare Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2017 | $3.5M | Series C | – | – | – |
| Nov 2016 | $5.5M | Series C | – | – | – |
| Jun 2015 | $12.1M | Series C | – | – | – |
| Dec 2014 | Debt – Conventional | – | – | – | |
| Dec 2014 | $1.3M | Series C | – | – | – |
| Oct 2014 | $750,000 | Series C | – | – | – |
| Oct 2014 | $750,000 | Debt – Conventional | – | – | – |
| Jun 2014 | $20M | Series C | – | – | |
| Mar 2013 | $3.56M | Series C | – | – | – |
| Oct 2008 | Series B | – | Longitude Capital, Healthcare Ventures |
6 investors in total: 6 institutional.
Investors in InfaCare Pharmaceuticals
InfaCare Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals, FirstMark and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| lookoutcapital.com | ||||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Early-stage venture capital is invested in tech startups across sectors. | 1987 | firstmark.com | New York, United States | |
| hcven.com | ||||
Specialty pharmaceutical products and diagnostic imaging agents are manufactured. | 1867 | mallinckrodt.com | St. Louis, United States |
Investor details for InfaCare Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of InfaCare Pharmaceuticals
4 dated milestones of InfaCare Pharmaceuticals across 16 years, from founding to its latest funding, stage changes and deals.
- Founded InfaCare Pharmaceuticals is founded.
- Funding First funding round of $75K.
- Funding Latest funding round, Series C, of $3.5M.
- Exit Acquired by Mallinckrodt Pharmaceuticals.
Competitors of InfaCare Pharmaceuticals
InfaCare Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. |
Detailed competitors of InfaCare Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as InfaCare Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Infacare Pharmaceuticals
Complete news archive for InfaCare Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InfaCare Pharmaceuticals
InfaCare Pharmaceuticals was founded in 2001 and raised its 1st funding round 1 year after it was founded.
InfaCare Pharmaceuticals is headquartered in Feasterville Trevose, United States. It is registered at Feasterville Trevose, Pennsylvania, United States.
InfaCare Pharmaceuticals is a funded company, having raised a total of $78.15M across 14 funding rounds to date.
InfaCare Pharmaceuticals was founded in 2001 and is based in Feasterville Trevose, United States. Operations focus on the specialty pharmaceutical sector, where treatments for neonatal and pediatric conditions are developed and brought to market. The lead product, Stanatea decyclizing heme oxygenase inhibitoris being advanced for hyperbilirubinemia in infants. Completion of the phase IIB Jasmine trial for stannsoporfin in neonates has been achieved.
InfaCare Pharmaceuticals's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Altimmune.
InfaCare Pharmaceuticals has 6 investors. Key investors include Mallinckrodt Pharmaceuticals, FirstMark, Atlas Venture, Lookout Capital, and Longitude Capital.
Yes. InfaCare Pharmaceuticals was acquired by Mallinckrodt Pharmaceuticals in September 2017.